Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Inflectra, Ixifi, Remicade, Renflexis, Avsola
Synonyms :
Class :
Antirheumatics, TNF alfa inhibitors
Brand Name :
Inflectra, Ixifi, Remicade, Renflexis, Avsola
Synonyms :
Class :
Antirheumatics, TNF alfa inhibitors
Dosage Forms & Strengths Â
Injection for reconstitution Â
100mg/vial Â
Administer dose of 3 mg/kg intravenously at 0, 2, and 6 weeks then administer every 8 weeks
Administer dose of 5 mg/kg intravenously at 0, 2, and 6 weeks then administer every 8 weeks
Start dose at week 10 or thereafter: Administer dose of 120 mg subcutaneously every 2 weeks
Administer dose of 5 mg/kg intravenously at 0, 2, and 6 weeks then administer every 6 weeks
Dosage Forms & Strengths Â
Injection for reconstitution Â
100mg/vial Â
For <6 years old: Not studied
For ≥6 to 17 years old: Administer dose of 5 mg/kg intravenously at 0, 2, and 6 weeks then every 8 weeks
For <6 years old: Not studied
For ≥6 years old: Administer dose of 5 mg/kg intravenously at 0, 2, and 6 weeks then every 8 weeks
may have an increased immunosuppressive effect when combined with anti-psoriasis agents
may have an increased immunosuppressive effect when combined with anti-psoriasis agents
may have an increased immunosuppressive effect when combined with anti-psoriasis agents
may have an increased immunosuppressive effect when combined with anti-psoriasis agents
may have an increased immunosuppressive effect when combined with anti-psoriasis agents
When infliximab is used in combination with rabies vaccine, this leads to a reduction in the rabies vaccine effects through the process of pharmacodynamic antagonism
When infliximab is used in combination with diphtheria & tetanus toxoids, this leads to a reduction in the effects of diphtheria & tetanus toxoids through pharmacodynamic antagonism
pneumococcal vaccine 13-valentÂ
infliximab diminishes the efficacy of the 13-valent pneumococcal vaccine through pharmacodynamic antagonism
when both drugs are combined, there may be an increased metabolism of etoposide   
when both drugs are combined, the metabolism of paclitaxel increases when compared with infliximab  
when both the drugs are combined, the metabolism of carmustine increases    
when both drugs are combined, there may be an increased risk or severity of adverse effects  
when both drugs are combined, there may be an increased risk or severity of adverse effects  
when both drugs are combined, there may be an increased risk of severe and potentially life-threatening infections   
when both drugs are combined, there may be an increased risk of severe life-threatening infections
in combination with ofatumumab, infliximab increases the risk of adverse events
when both drugs are combined, there may be an increased risk of severe and potentially life-threatening infections  
when both drugs are combined, there may be an increased risk or severity of adverse effects  
interaction raises immunosuppressive effects and risk of infection
may increase the toxic effect
may increase the immunosuppressive effect of anti-psoriatic agents
the toxicity of either of the drugs is increased by immunosuppressive activity
pneumococcal vaccine polyvalentÂ
the activity of pneumococcal vaccine polyvalent is reduced due to pharmacodynamic antagonism
It may enhance the risk of adverse effects when combined with biologic agents
It may enhance the risk of adverse effects when combined with biologic agents
It may enhance the risk of adverse effects when combined with biologic agents
It may enhance the risk of adverse effects when combined with biologic agents
It may enhance the risk of adverse effects when combined with biologic agents
When acetohexamide is used together with infliximab, this lead to rise in acetohexamide’s metabolism
both the drugs increase the effect of immunosuppression risk of infection increases on administering both the drugs simultaneously
may increase the risk of adverse effects when combined
may increase the risk or severity of adverse effects when combined
It may enhance the adverse effects when combined with sotrovimab
Adverse drug reactions:  Â
 Frequency Defined Â
>10% Â
Infection (36%) Â
Infusion-related reaction (20%) Â
Headache (18%) Â
Abdominal pain (12%; 26% with Crohn disease) Â
Diarrhea (12%) Â
Upper respiratory tract infection (32%) Â
Nausea (21%) Â
1-10%  Â
Rash (1-10%) Â
Bronchitis (10%) Â
Dyspepsia (10%) Â
Back pain (8%) Â
Rhinitis (8%) Â
Elevated ALT, ≥3 ULN (2-10%) Â
Fatigue (9%) Â
Urinary tract infection (8%) Â
Arthralgia  Â
Fever Â
Pregnancy warnings:    Â
AU TGA pregnancy category: CÂ
US FDA pregnancy category: Not assignedÂ
Lactation:Â
Excreted into human milk is unknownÂ
Pregnancy Categories:      Â
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester.      Â
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women      Â
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women      Â
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.      Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.      Â
Category N: There is no data available for the drug under this categoryÂ
Patient Information Leaflet   Â
Generic Name: infliximabÂ
Why do we use infliximab?Â
infliximab is a Antirheumatics, TNF alfa inhibitors used to treat number of inflammatory autoimmune diseases and Ulcerative Colitis.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
